In the case of femoral neck, there were significant improvements in BMD at 12 and 24 months with reference teriparatide, but the increases seen with teriparatide biosimilar did not reach statistical significance versus baseline at any timepoint (Fig. 1 b).
← all excerpts
Real-world efficacy of a teriparatide biosimilar (RGB-10) compared with reference teriparatide on bone mineral density, trabecular bone score, and bone parameters assessed using quantitative ultrasound, 3D-SHAPER<sup>®</sup> and high-resolution peripheral computer tomography in postmenopausal women with osteoporosis and very high fracture risk.
1
—
—